Study Profile Efficacy and safety of HS-20094 in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 2 trial Format: Short Oral Discussion Presentation#: 732 Corresponding author: Department of Endocrinology, Peking University First Hospital, Beijing, China, Junqing Zhang First author: Department of Endocrinology, Peking University First Hospital, Beijing, China, Lin Liu Date: September 12, 2024,14:00 (CEST) Introduction and Objective HS-20094 is a novel dual GIP and GLP-1 receptor agonist
In cell-free biochemical or protein-based models , Retatrutide supports investigation of binding kinetics, conformational dynamics, and interaction specificity
Ongoing paralysis may be useful initially to gain control of hyperthermia
Mechanisms like reducing inflammation, improving insulin sensitivity, and even influencing gut microbiota are being explored for their potential to benefit bone metabolism
A new medication in testing called retatrutide has also had reports of dysesthesia during clinical trials
Recent Pathophysiological Aspects of Peyronies Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review
